Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2001

01-05-2001

Short-Term Comparative Outcomes Associated with the Use of GP IIb/IIIa Antagonists in Patients Undergoing Coronary Intervention

Authors: Carey Kimmelstiel, Robert Phang, Asif Rehman, William Rand, Regina Miele, Joanne Rhofiry, Debra A. MacIsaac, William Gouveia, Donna Denier, Richard C. Becker

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2001

Login to get access
Metadata
Title
Short-Term Comparative Outcomes Associated with the Use of GP IIb/IIIa Antagonists in Patients Undergoing Coronary Intervention
Authors
Carey Kimmelstiel
Robert Phang
Asif Rehman
William Rand
Regina Miele
Joanne Rhofiry
Debra A. MacIsaac
William Gouveia
Donna Denier
Richard C. Becker
Publication date
01-05-2001
Publisher
Kluwer Academic Publishers
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2001
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1023/A:1011904718960

Other articles of this Issue 3/2001

Journal of Thrombosis and Thrombolysis 3/2001 Go to the issue

OriginalPaper

Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS): The New Thinking

OriginalPaper

Low Molecular Weight Heparin Therapy for Percutaneous Coronary Intervention: A Practice in Evolution

OriginalPaper

Elevation in Serum Troponin I Predicts the Benefit of Tirofiban

OriginalPaper

Applying Scientific Criteria to Therapeutic Interchange: A Balanced Analysis of Low-Molecular-Weight Heparins

OriginalPaper

Plasminogen Activator Inhibitor Type-1 (Part Two): Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents

OriginalPaper

Augmentation of In-Vitro Clot Dissolution by Low Frequency High-Intensity Ultrasound Combined with Antiplatelet and Antithrombotic Drugs
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits